PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-7.40%
Both companies show negative ROE. Martin Whitman would check if the entire market segment is distressed.
-6.83%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
-7.50%
Both companies show negative ROCE. Martin Whitman would investigate if external factors hamper profitability.
85.43%
Gross margin of 85.43% while CRVO is zero. Bruce Berkowitz would see if a small advantage can be leveraged.
-549.36%
Negative operating margin while CRVO has 0.00%. Joel Greenblatt would demand urgent improvements in cost or revenue.
-541.91%
Negative net margin while CRVO has 0.00%. Joel Greenblatt would check if uncompetitive pricing or bloated costs cause losses.